Home > Healthcare > Medical Devices > Diagnostic Devices > Point of Care Testing Market

Point of Care Testing Market Trends

Report ID: GMI3086
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Point of Care Testing Market Trends

The current trend in the point of care industry is strongly persuaded towards smart devices equipped with mobile healthcare that will significantly accelerate the progress of personalized healthcare monitoring and management. A wide range of mobile healthcare technologies, such as cell phone-based point of care technologies have grown largely preferred. For instance, in January 2022, Roche introduced the Cobas pulse system in countries that accept the CE Mark for combining professional blood glucose control with mobile digital medical capabilities to improve patient care. Moreover, the surging popularity of molecular diagnostics over conventional culture methods in obtaining timely results.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Point of care testing industry was valued at USD 38.6 billion in 2022 and is estimated to expand at 7% CAGR from 2023 to 2032 owing to the increasing prevalence of infectious diseases across developing countries.

The glucose monitoring segment accounted for 24.9% revenue share of the market in 2022 and is estimated to reach USD 19.2 billion by 2032 driven by the growing adoption of portable, highly convenient, and cost-effective as well as rapid POC glucose tests.

North America held 47.6% share of the market in 2022 and is anticipated to amass more than USD 35.6 billion by 2032 owing to the rising R&D investments and surge in private funding for healthcare infrastructure development.

Some of the top companies engaged in the industry are Becton, Dickinson and Company, Abbott Laboratories, F. Hoffmann-La Roche, Abaxis, ACON Laboratories, Inc, BioMerieux SA, Bio-Rad Laboratories, Inc, HemoCue AB (Danaher Corporation), Dexcom, Inc, and Medtronic Plc,